BR112012002445A2 - uso de um agonista do receptor 4 de melanocortina. - Google Patents
uso de um agonista do receptor 4 de melanocortina.Info
- Publication number
- BR112012002445A2 BR112012002445A2 BR112012002445A BR112012002445A BR112012002445A2 BR 112012002445 A2 BR112012002445 A2 BR 112012002445A2 BR 112012002445 A BR112012002445 A BR 112012002445A BR 112012002445 A BR112012002445 A BR 112012002445A BR 112012002445 A2 BR112012002445 A2 BR 112012002445A2
- Authority
- BR
- Brazil
- Prior art keywords
- agonist
- melanocortin receptor
- melanocortin
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27348809P | 2009-08-05 | 2009-08-05 | |
| PCT/US2010/043832 WO2011017209A1 (en) | 2009-08-05 | 2010-07-30 | Use of melanocortins to treat dyslipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002445A2 true BR112012002445A2 (pt) | 2015-10-13 |
Family
ID=43544604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002445A BR112012002445A2 (pt) | 2009-08-05 | 2010-07-30 | uso de um agonista do receptor 4 de melanocortina. |
Country Status (12)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2979703B1 (en) | 2007-11-05 | 2018-07-18 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
| WO2011060355A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S | Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2 |
| KR102038677B1 (ko) | 2011-06-14 | 2019-10-30 | 입센 파마 에스.에이.에스 | 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물 |
| SMT202100734T1 (it) | 2011-12-29 | 2022-03-21 | Rhythm Pharmaceuticals Inc | Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti |
| JP6538025B2 (ja) | 2013-03-15 | 2019-07-03 | リズム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物 |
| JP6622690B2 (ja) | 2013-03-15 | 2019-12-18 | リズム・ファーマシューティカルズ・インコーポレイテッド | ペプチド組成物 |
| MX2018003983A (es) | 2015-09-30 | 2018-11-09 | Rhythm Pharmaceuticals Inc | Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4. |
| WO2019219714A1 (en) * | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060148721A1 (en) * | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
| US20080306008A1 (en) * | 2004-11-04 | 2008-12-11 | Nova Nordisk A/S | Peptides for Use in the Treatment of Obesity |
| EP1915168A4 (en) * | 2005-07-08 | 2010-03-31 | Ipsen Pharma | LIGANDS OF MELANOCORTIN RECEPTORS |
| ES2663916T3 (es) * | 2005-07-08 | 2018-04-17 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| CA2689016C (en) * | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
| EP2979703B1 (en) * | 2007-11-05 | 2018-07-18 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
-
2010
- 2010-07-30 MX MX2012001513A patent/MX2012001513A/es not_active Application Discontinuation
- 2010-07-30 JP JP2012523666A patent/JP2013501053A/ja not_active Withdrawn
- 2010-07-30 US US13/388,387 patent/US20120135923A1/en not_active Abandoned
- 2010-07-30 BR BR112012002445A patent/BR112012002445A2/pt not_active IP Right Cessation
- 2010-07-30 IN IN1493DEN2012 patent/IN2012DN01493A/en unknown
- 2010-07-30 CA CA2769883A patent/CA2769883A1/en not_active Abandoned
- 2010-07-30 AU AU2010279719A patent/AU2010279719A1/en not_active Abandoned
- 2010-07-30 KR KR1020127005642A patent/KR20120059520A/ko not_active Ceased
- 2010-07-30 RU RU2012108110/15A patent/RU2012108110A/ru not_active Application Discontinuation
- 2010-07-30 CN CN2010800419706A patent/CN102548399A/zh active Pending
- 2010-07-30 WO PCT/US2010/043832 patent/WO2011017209A1/en not_active Ceased
- 2010-07-30 EP EP10806956.8A patent/EP2461681A4/en not_active Withdrawn
-
2013
- 2013-08-21 US US13/972,279 patent/US20130331324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2461681A1 (en) | 2012-06-13 |
| JP2013501053A (ja) | 2013-01-10 |
| CA2769883A1 (en) | 2011-02-10 |
| IN2012DN01493A (cg-RX-API-DMAC10.html) | 2015-06-05 |
| KR20120059520A (ko) | 2012-06-08 |
| EP2461681A4 (en) | 2013-04-24 |
| US20120135923A1 (en) | 2012-05-31 |
| MX2012001513A (es) | 2012-05-22 |
| US20130331324A1 (en) | 2013-12-12 |
| AU2010279719A1 (en) | 2012-03-01 |
| CN102548399A (zh) | 2012-07-04 |
| WO2011017209A1 (en) | 2011-02-10 |
| RU2012108110A (ru) | 2013-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200033I1 (hu) | CGRP receptor antagonisták | |
| EP2350060A4 (en) | Melanocortin receptor AGONISTS | |
| ATE524460T1 (de) | Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten | |
| BRPI0907364A2 (pt) | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina | |
| BR112012000107A2 (pt) | receptores de células t. | |
| BRPI0820508A2 (pt) | antagonistas de lna cujo alvo é o receptor de andrógeno | |
| BRPI0913930A2 (pt) | antagonistas de receptores de prostaglandinas d2 | |
| BRPI1008060A2 (pt) | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. | |
| BRPI0821668A2 (pt) | Uso | |
| BRPI0806500A2 (pt) | Agonistas gpcr de piperidina | |
| BRPI0910118A2 (pt) | antagonistas de receptores do glucagon | |
| EP2041120A4 (en) | MELANOCORTIN RECEPTOR AGONISTS | |
| BRPI1007017A2 (pt) | uso de um composto. | |
| BRPI0915134A2 (pt) | composto, e, uso de um composto | |
| EP2362779A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| DK3354273T3 (da) | Melanocortinreceptorligander | |
| BRPI0810926A2 (pt) | Antagonista de crig | |
| BRPI0812991A2 (pt) | Utilização de combustível melhorado | |
| EP2254413A4 (en) | IMIDAZOBENZAZEPIN-CGRP receptor antagonists | |
| BRPI1015091A2 (pt) | novo uso | |
| BRPI0720078A2 (pt) | 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a) | |
| DK2121630T3 (da) | Hurtigt dissocierende dopamin-2-receptor-antagonister | |
| BRPI1011036A2 (pt) | uso | |
| BR112012002824A2 (pt) | agonistas de receptor de esfingosina-1-fosfato | |
| BRPI1009763A2 (pt) | composição, e , uso de um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |